nach oben

Strahlentherapie und Onkologie

Erschienen in:

01.11.2013 | Original article

Reduction of rectal doses by removal of gas in the rectum during vaginal cuff brachytherapy

verfasst von: S. Sabater, Mª.M. Sevillano, I. Andres, R. Berenguer, S. Machin-Hamalainen, K. Müller, M. Arenas

Erschienen in: Strahlentherapie und Onkologie | Ausgabe 11/2013

Einloggen, um Zugang zu erhalten

Abstract

Objective

The goal of this work was to evaluate whether the volume reduction related to removal of gas in the rectum could be translated in lower doses to organs at risk (OAR) during vaginal cuff brachytherapy (VBT).

Material and methods

Fourteen pairs of brachytherapy planning CT scans derived from 11 patients were re-segmented and re-planned using the same parameters. The only difference between pairs of CTs was the presence or lack of gas in the rectum. The first CT showed the basal status and the second was carried out after gas removal with a tube. A set of values derived from bladder and rectum dose–volume histograms (DVH) and dose–surface histograms (DSH) were extracted. Moreover the cylinder position related to the patient craniocaudal axis was recorded.

Results

Rectum volume decreased significantly from 77.8 ± 45 to 55.43 ± 17.6 ml (p = 0.0052) after gas removal. Such volume diminution represented a significant reduction on all rectal DVH parameters analyzed except D_25 % and D_50 %. DSH parameter results were similar to previous ones. A nonsignificant increase of the bladder volume was observed and was associated with an increase of the DVH metrics analyzed.

Conclusion

Removal of gas pockets is a simple and inexpensive maneuver that decreases rectal dose parameters on VBT, which can be translated as a better therapeutic ratio. It also suggests that other actions directed to empty the rectum could have a similar effect.

Nout RA, Smit VT, Putter H et al (2010) Vaginal brachytherapy versus pelvic external beam radiotherapy for patients with endometrial cancer of high-intermediate risk (PORTEC-2): an open-label, non-inferiority, randomised trial. Lancet 375:816–823PubMedCrossRef

Nout RA, Putter H, Jurgenliemk-Schulz IM et al (2009) Quality of life after pelvic radiotherapy or vaginal brachytherapy for endometrial cancer: first results of the randomized PORTEC-2 trial. J Clin Oncol 27:3547–3556PubMedCrossRef

Choo JJ, Scudiere J, Bitterman P, Dickler A et al (2005) Vaginal lymphatic channel location and its implication for intracavitary brachytherapy radiation treatment. Brachytherapy 4:236–240PubMedCrossRef

Small W Jr, Du Bois A, Bhatnagar S et al (2009) Practice patterns of radiotherapy in endometrial cancer among member groups of the gynecologic cancer intergroup. Int J Gynecol Cancer 19:395–399PubMedCrossRef

Holloway CL, Macklin EA, Cormack RA, Viswanathan AN (2011) Should the organs at risk be contoured in vaginal cuff brachytherapy? Brachytherapy 10:313–317PubMedCrossRef

Hoskin PJ, Bownes P, Summers A (2002) The influence of applicator angle on dosimetry in vaginal vault brachytherapy. Br J Radiol 75:234–237PubMed

Hoskin PJ, Vidler K (2000) Vaginal vault brachytherapy: the effect of varying bladder volumes on normal tissue dosimetry. Br J Radiol 73:864–866PubMed

Hung J, Shen S, De Los Santos JF, Kim RY (2012) Image-based 3D treatment planning for vaginal cylinder brachytherapy: dosimetric effects of bladder filling on organs at risk. Int J Radiat Oncol Biol Phys 83:980–985PubMedCrossRef

Smeenk RJ, Teh BS, Butler EB et al (2010) Is there a role for endorectal balloons in prostate radiotherapy? A systematic review. Radiother Oncol 95:277–282PubMedCrossRef

10.

Ogino I, Uemura H, Inoue T, Kubota Y et al (2008) Reduction of prostate motion by removal of gas in rectum during radiotherapy. Int J Radiat Oncol Biol Phys 72:456–466PubMedCrossRef

11.

Sabater S, Andres A, Vara Olivas V de la et al (2013) Effect of rectal distention on vaginal cuff brachytherapy. Radiother Oncol 106(S2):s365–s366

12.

Schmid MP, Mansmann B, Federico M et al (2013) Residual tumour volumes and grey zones after external beam radiotherapy (with or without chemotherapy) in cervical cancer patients. A low-field MRI study. Strahlenther Onkol 189:238–244PubMedCrossRef

13.

Keys HM, Roberts JA, Brunetto VL et al (2004) A phase III trial of surgery with or without adjunctive external pelvic radiation therapy in intermediate risk endometrial adenocarcinoma: a Gynecologic Oncology Group study. Gynecol Oncol 92:744–751PubMedCrossRef

14.

Aalders J, Abeler V, Kolstad P, Onsrud M (1980) Postoperative external irradiation and prognostic parameters in stage I endometrial carcinoma: clinical and histopathologic study of 540 patients. Obstet Gynecol 56:419–427PubMed

15.

Sorbe B, Nordstrom B, Maenpaa J et al (2009) Intravaginal brachytherapy in FIGO stage I low-risk endometrial cancer: a controlled randomized study. Int J Gynecol Cancer 19:873–878PubMedCrossRef

16.

Rovirosa A, Ascaso C, Sanchez-Reyes A et al (2011) Three or four fractions of 4–5 Gy per week in postoperative high-dose-rate brachytherapy for endometrial carcinoma. Int J Radiat Oncol Biol Phys 81:418–423PubMedCrossRef

17.

Rovirosa A, Valduvieco I, Ascaso C et al (2013) Daily schedule for high-dose-rate brachytherapy in postoperative treatment of endometrial carcinoma. Clin Transl Oncol 15:111–116PubMedCrossRef

18.

Kim RY, Shen S, Lin HY et al (2010) Effects of bladder distension on organs at risk in 3D image-based planning of intracavitary brachytherapy for cervical cancer. Int J Radiat Oncol Biol Phys 76:485–489PubMedCrossRef

19.

Stewart AJ, Cormack RA, Lee H et al (2008) Prospective clinical trial of bladder filling and three-dimensional dosimetry in high-dose-rate vaginal cuff brachytherapy. Int J Radiat Oncol Biol Phys 72:843–848PubMedCrossRef

20.

Sun L-M, Huang H-Y, Huang E-Y et al (2005) A prospective study to assess the bladder distension effects on dosimetry in intracavitary brachytherapy of cervical cancer via computed tomography-assisted techniques. Radiother Oncol 77:77–82PubMedCrossRef

21.

Onishi H, Kuriyama K, Komiyama T et al (2012) Large prostate motion produced by anal contraction. Radiother Oncol 104:390–394PubMedCrossRef

22.

Nag S, Erickson B, Parikh S et al (2000) The American Brachytherapy Society recommendations for high-dose-rate brachytherapy for carcinoma of the endometrium. Int J Radiat Oncol Biol Phys 48:779–790PubMedCrossRef

23.

Small W, Beriwal S, Demanes DJ et al (2012) American Brachytherapy Society consensus guidelines for adjuvant vaginal cuff brachytherapy after hysterectomy. Brachytherapy 11:58–67PubMedCrossRef

24.

Potter R, Gerbaulet A, Haie-Meder C (2002) Endometrial cancer. The GEC ESTRO handbook of brachytherapy. ESTRO, Leuven, pp 365–401

25.

Olszewska AM, Saarnak AE, Boer RW de et al (2001) Comparison of dose–volume histograms and dose–wall histograms of the rectum of patients treated with intracavitary brachytherapy. Radiother Oncol 61:83–85PubMedCrossRef

Titel: Reduction of rectal doses by removal of gas in the rectum during vaginal cuff brachytherapy
verfasst von: S. Sabater
Mª.M. Sevillano
I. Andres
R. Berenguer
S. Machin-Hamalainen
K. Müller
M. Arenas
Publikationsdatum: 01.11.2013
Verlag: Springer Berlin Heidelberg
Erschienen in: Strahlentherapie und Onkologie / Ausgabe 11/2013
Print ISSN: 0179-7158
Elektronische ISSN: 1439-099X
DOI: https://doi.org/10.1007/s00066-013-0427-x

Springer Medizin

Reduction of rectal doses by removal of gas in the rectum during vaginal cuff brachytherapy

Abstract

Objective

Material and methods

Results

Conclusion

Neu im Fachgebiet Onkologie

Adjuvante Immuntherapie verlängert Leben bei RCC

Alectinib verbessert krankheitsfreies Überleben bei ALK-positivem NSCLC

Bei Senioren mit Prostatakarzinom auf Anämie achten!

ICI-Therapie in der Schwangerschaft wird gut toleriert

Update Onkologie

Springer Medizin

Abstract

Objective

Material and methods

Results

Conclusion

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 11/2013

RCT mit 5-FU und Mitomycin C mit 28 Fraktionen á 1,8 Gy einer externen Strahlentherapie bleibt Behandlungsstandard beim Analkarzinom

Concurrent and adjuvant temozolomide-based chemoradiotherapy schedules for glioblastoma

Treatment of astrocytoma grade III with Photofrin II as a radiosensitizer

A novel surface imaging system for patient positioning and surveillance during radiotherapy

Radiosensitization by histone deacetylase inhibition in an osteosarcoma mouse model

Vorhersage lokoregionärer Rezidive nach radikaler Blasenentfernung von Urothelkarzinomen

Neu im Fachgebiet Onkologie

Adjuvante Immuntherapie verlängert Leben bei RCC

Alectinib verbessert krankheitsfreies Überleben bei ALK-positivem NSCLC

Bei Senioren mit Prostatakarzinom auf Anämie achten!

ICI-Therapie in der Schwangerschaft wird gut toleriert

Update Onkologie